Ziad Nasreddine, MD, FRCP(C), provides his insights on the case study’s cognitive assessments and highlights the presence of some ‘red flags’ in the results. He outlines his approach for evaluating memory complaints in clinical practice and how various clinical assessment tools can be used at different points in the AD continuum. Dr. Nasreddine then describes the Montreal Cognitive Assessment (MoCA) in detail, including the diagnostic accuracy of the scale and recommended follow up.
Professor Frisoni provides further details from the case study, including fluorodeoxyglucose (FDG)-positron emission tomography (PET) imaging, cerebrospinal fluid (CSF) analysis, and amyloid and tau PET results.
Disclosure: All panelists received honoraria from Biogen for participation in this symposium.
Disclaimer: All of the information discussed today is for informational purposes only; does not constitute medical advice; and is not intended to be a substitute for independent professional medical judgment, advice, diagnosis, or treatment.